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Aims Hyperkalaemia in heart failure patients limits use of cardioprotective renin–angiotensin–aldosterone system
inhibitors (RAASi). Sodium zirconium cyclosilicate (ZS-9) is a selective potassium ion trap, whose mechanism of
action may allow for potassium binding in the upper gastrointestinal tract as early as the duodenum following oral
administration. ZS-9 previously demonstrated the ability to reduce elevated potassium levels into the normal range,
with a median time of normalization of 2.2 h and sustain normal potassium levels for 28 days in HARMONIZE—a
Phase 3, double-blind, randomized, placebo-controlled trial. In the present study we evaluated management of serum
potassium with daily ZS-9 over 28 days in heart failure patients from HARMONIZE, including those receiving RAASi
therapies.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Methods
and results
Heart failure patients with evidence of hyperkalaemia (serum potassium ≥5.1mmol/L, n= 94) were treated
with open-label ZS-9 for 48 h. Patients (n= 87; 60 receiving RAASi) who achieved normokalaemia (potassium
3.5–5.0mmol/L) were randomized to daily ZS-9 (5, 10, or 15 g) or placebo for 28 days. Mean potassium and
proportion of patients maintaining normokalaemia during days 8–29 post-randomization were evaluated. Despite
RAASi doses being kept constant, patients on 5 g, 10 g, and 15 g ZS-9 maintained a lower potassium level (4.7mmol/L,
4.5mmol/L, and 4.4mmol/L, respectively) than the placebo group (5.2mmol/L; P<0.01 vs. each ZS-9 group); greater
proportions of ZS-9 patients (83%, 89%, and 92%, respectively) maintained normokalaemia than placebo (40%;
P< 0.01 vs. each ZS-9 group). The safety profile was consistent with previously reported overall study population.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Conclusion Compared with placebo, all three ZS-9 doses lowered potassium and effectively maintained normokalaemia for
28 days in heart failure patients without adjusting concomitant RAASi, while maintaining a safety profile consistent
with the overall study population.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Introduction
Hyperkalaemia is a life-threatening condition associated with
serious cardiac arrhythmias, conduction system abnormalities, and
increased mortality.1,2 The prevalence of hyperkalaemia has been
increasing because of higher rates of patients with chronic kidney
disease (CKD), heart failure (HF), and diabetes, as well as the
broader use of renin–angiotensin–aldosterone system inhibitors
(RAASi).3–5 Specifically, the growing use of RAASi and mineralo-
corticoid receptor antagonists (MRAs)—as a result of proven
clinical benefit in at-risk populations (particularly those with
HF)—has led to higher rates of hyperkalaemia and related hos-
pitalizations and deaths as these agents increase serum potassium
levels as a result of their mechanism of action.6 Commonly used
treatments for hyperkalaemia, such as polymer exchange resins
[i.e. sodium polystyrene sulphonate (SPS)] have significant limita-
tions, including not having been evaluated in randomized trials.7–9
Furthermore, SPS is poorly tolerated, associated with severe and
even fatal gastrointestinal (GI) complications, calling into question
its suitability for chronic use.10–13 Other management strategies
for hyperkalaemia, including restricted dietary intake of potassium
and treatments such as insulin, sodium bicarbonate, and inhaled
beta-2-adrenergic agonists, have shown limited and temporary
efficacy, and are not always feasible.14–16
RAASi, including angiotensin-converting enzyme inhibitors
(ACEi), angiotensin receptor blockers (ARB), and MRAs have
been shown to decrease morbidity and mortality in patients
with HF,17–19 but are also known to impair potassium excretion,
particularly when given at full dose.20–22 Discontinuation or
dose reduction of such therapies decreases hyperkalaemia but is
associated with substantial long-term risk because of the signifi-
cant cardiorenal benefit associated with their use. Consequently,
although clinical trials have indicated that optimal ACEi, ARB, and
MRA dosing may reduce cardiovascular-related hospitalizations
and mortality,21 utilization studies have demonstrated that RAASi
dosing is often not optimized in HF patients,23–25 with renal
dysfunction and hyperkalaemia frequently cited as barriers to
optimal application of RAASi in daily clinical practice.26–28
Several studies have documented that only approximately
one-third of HF patients eligible for RAASi therapy are receiving
the target dose.29,30 Optimal dosing of RAASi may be increased in
patients with HF, if hyperkalaemia is addressed and properly man-
aged in these patients. However, current standard-of-care therapies
for hyperkalaemia, including agents such as SPS, have uncertain
efficacy, poor tolerability, and are associated with severe GI
toxicity.10,31 There is a clinical need for agents that can reliably and
safely reduce serum potassium in patients with HF, and effectively
maintain normal potassium in patients who are receiving RAASi.
Sodium zirconium cyclosilicate (ZS-9) is an orally administered,
non-absorbed, highly selective K+ ion trap, which binds potassium
even in the presence of competing ions throughout the intestinal
tract. Preclinical studies have suggested that ZS-9 exerts its greatest
effects in the duodenum.32 The results of two recently published
phase 3 randomized trials in over 1000 patients demonstrated that
ZS-9 rapidly normalized serum potassium levels and maintained ..
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.. potassium in the normal range in a broad cross-section of hyper-
kalaemic patients.33,34 In the phase 3 Hyperkalaemia Randomized
Intervention Multidose ZS-9 Maintenance (HARMONIZE) study
of 258 patients with hyperkalaemia, treatment with ZS-9 resulted
in rapid and significant reductions in potassium from 5.6mmol/L
at baseline to 4.5mmol/L at 48 h, with a median time to normal-
ization of 2.2 h. After achieving normal potassium levels, patients
were randomized to receive placebo (treatment withdrawal) or
ZS-9 (5, 10, or 15 g) for 28 days; during this randomized phase, all
three doses of ZS-9 resulted in significantly lower potassium levels
and greater proportion of patients maintaining normokalaemia vs.
placebo, while demonstrating a safety profile similar to placebo,
with no ZS-9 treatment-related serious adverse events and no
impact on magnesium.34
In this study, we specifically focused on the efficacy of ZS-9 in
maintaining normal potassium levels in HF patients who partici-
pated in the HARMONIZE study.
Methods
Study population
The details of the HARMONIZE study are reported elswhere.34
The study recruited adult ambulatory patients with hyperkalaemia
(serum potassium ≥5.1mmol/L) from 44 cardiology, nephrology
and general research sites in the USA, Australia, and South Africa
(March–August 2014). Key exclusion criteria were renal dialysis,
active and significant cardiac arrhythmias and treatment with SPS.
Patients initially received open-label ZS-9 10 g TID for 48 h; those
achieving normokalaemia (serum potassium 3.5–5.0mmol/L) were
randomized (4 : 4 : 4 : 7) to ZS-9 (5, 10 or 15 g) or placebo once
daily for 28 days (Figure1). Concomitant medications could not be
adjusted per protocol. Patients completing the randomized phase
were eligible for entry in an 11-month open-label extension phase.
For this analysis, we specifically focused on patients with a history
of HF who participated in the HARMONIZE trial. Patients who
developed significant hypokalaemia (serum potassium <3.0mmol/L)
at any time, severe hyperkalaemia (serum potassium >6.2mmol/L) or
significant arrhythmias (ventricular tachycardia/fibrillation, new atrial
fibrillation/flutter, paroxysmal supraventricular tachycardia, second- or
Figure 1 Study design overview. Patients with hyperkalaemia
and a history of heart failure (HF) in the Hyperkalaemia Random-
ized Intervention Multidose ZS-9 Maintenance (HARMONIZE)
study received ZS-9 10 g during the 48-h open-label phase. Those
who achieved normokalaemia were randomized to placebo (ran-
domized withdrawal) or ZS-9 (5 g, 10 g, or 15 g) for 28 days.
© 2015 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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third-degree atrioventricular block or significant bradycardia [heart
rate <40 bpm]) during the maintenance phase were withdrawn from
the study and referred to their treating physician.
The study was conducted in accordance with the ICH E6 (R1)
guidelines of good clinical practice and the declaration of Helsinki.
The study was approved by national regulatory authorities in each
country and the institutional review board or local ethics committee
for each site.
Potassium measurements
All potassium levels were measured (after an 8-h fast) in whole blood
with a point-of-care device (i-STAT; Abbott Laboratories, Princeton,
NJ). All samples were then sent to a central laboratory for analysis
(AU680 chemistry analyzer; Beckman-Coulter, Brea, CA). Patient eli-
gibility for randomization was based on i-STAT potassium values in
the morning of study day 3 (following 48 h of treatment with ZS-9 at
10 g, this times daily, TID, to lower potassium). Following randomiza-
tion, potassium was measured pre-dose on select days throughout the
28-day randomized phase of the study. Statistical analyses were based
on central laboratory values. No protocol-directed advice on dietary
potassium was provided to patients.
The primary outcome for this analysis was mean serum potas-
sium, determined from days 8 to 29 after randomization. Other out-
comes included the proportion of patients that were normokalaemic
(mean potassium <5.1mmol/L) during days 8–29 following random-
ization and adverse events. Per protocol, secondary objectives of
HARMONIZE included evaluation of safety and efficacy of ZS-9 in
patients with HF. Patients in HARMONIZE who met eligibility crite-
ria could enrol in an open-label extension phase of once-daily ZS-9 for
11months (NCT02107092).
Statistical analysis
All statistical analyses were conducted as previously described.34
Briefly, a longitudinal generalized estimating equation (GEE) model was
used to simultaneously compare each active dose (highest to lowest)
vs. placebo for the mean day 8–29 values. The GEE model is a repeated
measure, mixed effect model. Fisher Exact test was used to mea-
sure proportion of normokalaemic patients at measured time-intervals
and patients with mean day 8–29 potassium <5.1mmol/L. For the
open-label phase efficacy endpoints, change from baseline in potas-
sium at all time-points were assessed using one-sample t-test to test
the null hypotheses that the mean changes from baseline were 0. A
two-sided P-value of<0.05 was considered statistically significant for all
endpoints. All analyses were conducted using SAS v9.1 (SAS Institute,
Inc., Cary, NC, USA).
Results
Study population
Of 94 patients who had a history of HF at baseline, 87 (93%)
achieved normokalaemia after 48 h of ZS-9 treatment and were
randomized to either once-daily ZS-9 at the 5 g (n=18), 10 g
(n= 18), or 15 g (n= 25) dose, or placebo (n= 26). Of the seven
patients who were not randomized, two withdrew consent before
completing the open-label phase, and five completed the 48-h
open-label phase but withdrew because they did not meet the ..
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.. serum potassium target (3.5–5.0mmol/L; n= 4), as determined
by a local i-STAT device, or did meet electrocardiogram (ECG)
withdrawal criteria (n=1).
Baseline characteristics are listed in Table 1. Across patients,
the median age was 69 years, 64% were male, and 86% were
white; 71% of patients had a history of diabetes mellitus, 76%
had a history of chronic kidney disease, and 81% had estimated
glomerular filtration rate (eGFR) of <60mL/min.1.73m2. At
baseline, 69% of patients were treated with RAASi (44% on ACEi,
23% on ARB, and 11% on MRA), which were continued for the
duration of the study in all patients receiving these agents. Of
these patients, 43% had mild hyperkalaemia (serum potassium
5.0 to <5.5mmol/L), 45% had moderate hyperkalaemia (serum
potassium 5.5 to <6.0mmol/L), and 13% had severe hyperkalaemia
(potassium ≥6.0mmol/L) at baseline.
Efficacy
Before randomization, the mean baseline serum potassium in 94
patients with HF was 5.6mmol/L [95% confidence interval (CI)
5.5–5.7], which was normalized to 4.4mmol/L (95% CI 4.3–4.5)
after 48 h of ZS-9 treatment (Figure 2). The median time to normal-
ization was 2.0 h.Within 24 h, 90% of patients had serum potassium
<5.1mmol/L; within 48 h, 99% of patients had serum potassium
<5.1mmol/L.
During the 28-day randomized withdrawal phase, patients
in the 5 g, 10 g, and 15 g dose groups maintained lower serum
potassium levels at 4.7mmol/L (95% CI 4.5–4.9), 4.5mmol/L
(95% CI 4.3–4.6), and 4.4mmol/L (95% CI 4.2–4.5), respectively,
compared with patients on placebo who returned to hyper-
kalaemia [5.2mmol/L; 95% CI 5.0–5.4; P< 0.001, ZS-9 (all doses)
vs. placebo; Figures 3 and 4]. Greater proportions of HF patients
receiving ZS-9 maintained normokalaemia (mean potassium
<5.1mmol/L, days 8–29) during the randomized phase (83%,
89%, and 92% of patients in the 5 g, 10 g, and 15 g dose groups,
respectively) compared with the placebo arm [40%; P< 0.01 for
ZS-9 (all doses) vs. placebo]. Efficacy findings were consistent
among HF patients regardless of continued concomitant RAASi
medication.
Safety
Adverse events were reported in 10 HF patients (10.6%) in the
48-h open-label phase; nausea and dizziness were the most com-
mon, occurring in two patients (2.1%) each. Adverse events occur-
ring in two or more HF patients after randomization are presented
in Table 2. The most commonly reported adverse event during the
maintenance phase was oedema, occurring in one, two, and five
patients in the 5 g, 10 g, and 15 g dose groups, respectively, and one
patient in the placebo arm. Eight of the nine cases were peripheral
oedema, four of which did not require treatment despite contin-
ued ZS-9 dosing, and no patient discontinued the study because of
oedema. Generalized oedema occurred in one patient with severe
HF and a history of oedema requiring diuretic treatment. This
occurrence of oedema was attributed to discontinuation of diuret-
ics by the patient’s family physician before initiation of the study.
© 2015 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Baseline characteristics of heart failure patients by treatment arm
Open-label phase Randomized phase
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ZS-9 10 g (n= 94) Placebo (n= 26) ZS-9 dose
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5 g (n=18) 10 g (n=18) 15 g (n= 25)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Median age, years (range) 69.0 (36–89) 69.0 (45–82) 70.5 (48–89) 69.0 (46–85) 68.0 (36–82)
Sex, n (%)
Male 60 (63.8) 16 (61.5) 12 (66.7) 9 (50.0) 20 (80.0)
Female 34 (36.2) 10 (38.5) 6 (33.3) 9 (50.0) 5 (20.0)
Race, n (%)
White 81 (86.2) 22 (84.6) 16 (88.9) 15 (83.3) 21 (84.0)
Black/African American 12 (12.8) 3 (11.5) 2 (11.1) 3 (16.7) 4 (16.0)
Serum potassium, n (%)
<5.5mmol/L 40 (42.6) 12 (46.2) 6 (33.3) 6 (33.3) 11 (44.0)
5.5 to <6.0mmol/L 42 (44.7) 10 (38.5) 11 (61.1) 9 (50.0) 11 (44.0)
≥6.0mmol/L 12 (12.8) 4 (15.4) 1 (5.6) 3 (16.7) 3 (12.0)
eGFR, n (%)
<30mL/min.1.73m2 39 (41.4) 8 (30.8) 8 (44.4) 9 (50.0) 10 (40)
<60mL/min.1.73m2 76 (80.9) 22 (84.6) 13 (72.2) 16 (88.9) 20 (80.0)
Comorbidities, n (%)a
Chronic kidney disease 71 (75.5) 19 (73.1) 12 (66.7) 15 (83.3) 18 (72.0)
Diabetes mellitus 67 (71.3) 18 (69.2) 13 (72.2) 16 (88.9) 17 (68.0)
Heart failure 94 (100) 26 (100) 18 (100) 18 (100) 25 (100)
RAASi medication, n (%) 65 (69.1) 21 (80.8) 11 (61.1) 14 (77.8) 14 (56.0)
ACEi 41 (43.6) 18 (69.2) 5 (27.8) 7 (38.9) 11 (44.0)
ARB 22 (23.4) 3 (11.5) 5 (27.8) 6 (33.3) 3 (12.0)
MRA 10 (10.6) 4 (15.4) 2 (11.1) 2 (11.1) 1 (4.0)
ACE, angiotensin-converting enzyme; ARB, angiotensin-receptor blockers; eGFR, estimated glomerular filtration rate; MRA, mineralocorticoid receptor antagonists; RAASi,
renin-angiotensin-aldosterone system inhibitor.
aHistory of chronic kidney disease or diabetes mellitus collected at study entry.
Figure 2 Mean serum potassium over time in patients treated
with ZS-9 10 g three times daily (circles) for 48 h during the
open-label phase. The shaded portion represents normal potas-
sium levels. Bars indicate 95% confidence intervals. Triangles indi-
cate administration of ZS-9 dose. *P< 0.001 for comparisons
against placebo.
Six of the nine oedema patients entered the extension study, con-
tinuing once-daily ZS-9, and none have experienced new oedema
(with 149 total exposure weeks). No patient receiving 15 g doses
of ZS-9 in the extension study has experienced oedema (with 278
total exposure weeks). Notably, the oedema rate in HF patients in .
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Figure 3 Mean serum potassium, days 8–29 after randomiza-
tion, placebo vs. ZS-9 5 g, 10 g, and 15 g dose groups. Mean
baseline serum potassium values before and after 48 h of ZS-9
treatment are shown below the graph for each dose group. The
shaded portion represents normal potassium levels. Bars indi-
cate 95% confidence interval. *P< 0.001 for comparisons against
placebo.
the extension study is numerically lower than the oedema rate in
HF patients on placebo during the randomized phase (0.00119 vs.
0.00132 oedema per day of exposure).
Gastrointestinal events were reported in five patients (5.3%) dur-
ing the open-label phase. After randomization, GI events occurred
© 2015 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 4 Mean serum potassium over time for the duration
of the study (circles): (A) placebo (n= 25), (B) ZS-9 5 g dose
group (n=18), (C) ZS-9 10 g dose group (n= 18), and (D) ZS-9
15 g dose group (n= 24). Triangles indicate administration of
ZS-9 dose or placebo. The shaded portion represents normal
potassium levels. Bars indicate 95% confidence intervals. *P< 0.05
for comparisons against placebo.
in one patient (5.6%) in the 5 g dose group, none in the 10 g dose
group, and three (12%) in the 15 g dose group, compared with
five (19.2%) in the placebo group. No clinically significant cases of
hypokalaemia (serum potassium <3.0mmol/L) or cardiac arrhyth-
mias occurred. Laboratory analyses showed mild hypokalaemia (3.0
to <3.5mmol/L) occurring in one patient in the 10 g dose group ..
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.. and three patients in the 15 g dose group; each case resolved
with protocol-directed dose adjustments. None of the cases of
hypokalaemia were reported as adverse events. There were no
treatment-related serious adverse events in any ZS-9 dose groups.
Discussion
Angiotensin-converting enzyme inhibitor, ARB, and MRA therapy
are cornerstones of modern HF therapy, decreasing morbidity and
mortality in patients with HF. Unfortunately, these RAASi therapies
impair potassium excretion, thereby causing or exacerbating hyper-
kalaemia. The development of hyperkalaemia in HF patients often
results in the reduction RAASi dosage to a level that is subopti-
mal for the treatment of their cardiovascular disease. Our current
options for hyperkalaemia are not ideal given that they are tran-
sient, require active management, and are invasive and expensive.
For example, treatments such as insulin, sodium bicarbonate, and
inhaled beta-2-adrenergic agonists cause a temporary intracellular
shift of potassium, dialysis is costly and invasive, and organic poly-
mer resins have not been evaluated in randomized trials and are
associated with severe GI complications.
In the present paper we describe the safety and efficacy
of once-daily ZS-9 to achieve and maintain normokalaemia in
HF patients with hyperkalaemia. Our findings in HF patients
with hyperkalaemia demonstrate that, compared with placebo,
once-daily ZS-9 resulted in lower potassium levels and greater
proportion of patients who maintained normokalaemia for up to
4weeks. The majority of patients (69%) received RAASi during
the study and achieved and maintained normokalaemia without
adjustment of their RAASi dose. The data described here in HF
patients are consistent with results from two phase 3 randomized
controlled trials where ZS-9 rapidly normalized serum potassium
within hours and continued to maintain normal potassium for up
to 28 days in a high proportion of patients on all ZS-9 doses, all
ZS-9 doses reduced serum aldosterone, and efficacy was similar
across patients on and not on RAASi. These results suggest that
in HF patients, including those on ACEi, ARB, and/or MRA, ZS-9
demonstrated a safety profile similar to the overall HARMONIZE
population, was fast-acting with a median time to serum potassium
normalization of 2 h, and maintained normokalaemia in patients
with HF without the need to reduce or cease life-saving RAASi
therapies.
The results of this study should be interpreted in the context
of several potential limitations. First, our analysis focused on the
subgroup of patients with HF from the HARMONIZE study popula-
tion, the numbers of patients within each treatment subgroup were
small, and interpretability of the results must take into considera-
tion the limitations inherent to treatment in a clinical trial setting.
A diagnosis of HF was established based on patient history; no
data were collected on New York Heart Association (NYHA) class,
echocardiogram, or ejection fraction of enrolled patients. Sec-
ond, hospitalized patients, those receiving dialysis, and those with
life-threatening arrhythmias were excluded from the HARMONIZE
trial. Third, although the findings of this study support the ability of
ZS-9 to enable continuation of RAASi use in HF patients, additional
© 2015 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 Summary of all adverse events occurring in two or more patients in any treatment arm
Adverse event, n Placebo (n= 26) ZS-9 dose
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5 g (n= 18) 10 g (n= 18) 15 g (n= 25)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Any event 9 10 7 15
Oedemaa 1 1 2 5b
Fatigue 0 0 1 2
Anaemia 0 0 0 2
Nasopharyngitis 1 0 0 2
Upper respiratory tract infection 0 2 0 0
Hypertension 1 1 1 2
aEight of the nine cases were peripheral oedema, four of which did not require treatment despite continued ZS-9 treatment, and no patient discontinued the study because
of oedema. Six of nine patients entered the extension study and none have experienced new oedema (149 total exposure weeks).
bGeneralized oedema occurred in one patient with severe heart failure and a history of oedema requiring diuretic treatment. This occurrence of oedema was attributed to
discontinuation of diuretics by the patient’s family physician before initiation of the study.
studies will be valuable in confirming whether ZS-9 use can enable
up-titration or optimal dosing of RAASi in these patients. Finally,
the HARMONIZE trial followed patients for up to 4weeks, there-
fore the long-term evaluation of ZS-9 efficacy and safety would be
valuable and these studies are currently ongoing.
In conclusion, compared with placebo, all three doses of ZS-9
resulted in lower potassium levels and effectively maintained
normokalaemia for 28 days in hyperkalaemic patients with HF,
including those on RAASi. These data suggest that ZS-9 may enable
continuation of important RAASi use in patients with HF and rep-
resents a promising addition to the future of HF therapy.
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